vs
Side-by-side financial comparison of Fulgent Genetics, Inc. (FLGT) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
SMITH & WESSON BRANDS, INC. is the larger business by last-quarter revenue ($124.7M vs $83.3M, roughly 1.5× Fulgent Genetics, Inc.). SMITH & WESSON BRANDS, INC. runs the higher net margin — 1.5% vs -28.1%, a 29.6% gap on every dollar of revenue. On growth, Fulgent Genetics, Inc. posted the faster year-over-year revenue change (9.3% vs -3.9%). SMITH & WESSON BRANDS, INC. produced more free cash flow last quarter ($16.3M vs $-83.1M). Over the past eight quarters, Fulgent Genetics, Inc.'s revenue compounded faster (13.7% CAGR vs -4.8%).
Fulgent Genetics, Inc. is a molecular diagnostics technology firm that develops and offers genetic testing services including carrier screening, oncology testing, infectious disease detection, and hereditary condition analysis, serving clinical providers, pharma firms, research institutions and public health groups primarily in North America.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
FLGT vs SWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.3M | $124.7M |
| Net Profit | $-23.4M | $1.9M |
| Gross Margin | 39.1% | 24.3% |
| Operating Margin | -43.5% | 3.3% |
| Net Margin | -28.1% | 1.5% |
| Revenue YoY | 9.3% | -3.9% |
| Net Profit YoY | -297.7% | -53.6% |
| EPS (diluted) | — | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $83.3M | $124.7M | ||
| Q3 25 | $84.1M | $85.1M | ||
| Q2 25 | $81.8M | $140.8M | ||
| Q1 25 | $73.5M | $115.9M | ||
| Q4 24 | $76.2M | $129.7M | ||
| Q3 24 | $71.7M | $88.3M | ||
| Q2 24 | $71.0M | $159.1M | ||
| Q1 24 | $64.5M | $137.5M |
| Q4 25 | $-23.4M | $1.9M | ||
| Q3 25 | $-6.6M | $-3.4M | ||
| Q2 25 | $-19.0M | $8.6M | ||
| Q1 25 | $-11.5M | $2.1M | ||
| Q4 24 | $-5.9M | $4.5M | ||
| Q3 24 | $-14.6M | $-1.9M | ||
| Q2 24 | $-8.7M | $27.9M | ||
| Q1 24 | $-13.5M | $7.9M |
| Q4 25 | 39.1% | 24.3% | ||
| Q3 25 | 42.2% | 25.9% | ||
| Q2 25 | 42.1% | 28.8% | ||
| Q1 25 | 38.6% | 24.1% | ||
| Q4 24 | 41.8% | 26.6% | ||
| Q3 24 | 37.3% | 27.4% | ||
| Q2 24 | 37.3% | 35.5% | ||
| Q1 24 | 34.3% | 28.7% |
| Q4 25 | -43.5% | 3.3% | ||
| Q3 25 | -18.3% | -3.5% | ||
| Q2 25 | -24.1% | 9.3% | ||
| Q1 25 | -26.9% | 4.1% | ||
| Q4 24 | -21.2% | 5.8% | ||
| Q3 24 | -23.8% | -1.7% | ||
| Q2 24 | -26.6% | 17.4% | ||
| Q1 24 | -33.8% | 8.2% |
| Q4 25 | -28.1% | 1.5% | ||
| Q3 25 | -7.9% | -4.0% | ||
| Q2 25 | -23.2% | 6.1% | ||
| Q1 25 | -15.7% | 1.8% | ||
| Q4 24 | -7.7% | 3.5% | ||
| Q3 24 | -20.4% | -2.1% | ||
| Q2 24 | -12.3% | 17.5% | ||
| Q1 24 | -20.9% | 5.7% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $0.19 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $0.60 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.2M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $363.2M |
| Total Assets | $1.2B | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.2M | $22.4M | ||
| Q3 25 | $117.6M | $18.0M | ||
| Q2 25 | $87.9M | $25.2M | ||
| Q1 25 | $67.3M | $26.7M | ||
| Q4 24 | $55.1M | $39.1M | ||
| Q3 24 | $58.0M | $35.5M | ||
| Q2 24 | $65.1M | $60.8M | ||
| Q1 24 | $54.7M | $47.4M |
| Q4 25 | $1.1B | $363.2M | ||
| Q3 25 | $1.1B | $364.4M | ||
| Q2 25 | $1.1B | $372.5M | ||
| Q1 25 | $1.1B | $366.9M | ||
| Q4 24 | $1.1B | $371.5M | ||
| Q3 24 | $1.1B | $380.0M | ||
| Q2 24 | $1.1B | $399.9M | ||
| Q1 24 | $1.1B | $376.4M |
| Q4 25 | $1.2B | $548.6M | ||
| Q3 25 | $1.2B | $554.6M | ||
| Q2 25 | $1.2B | $559.6M | ||
| Q1 25 | $1.2B | $578.9M | ||
| Q4 24 | $1.2B | $587.4M | ||
| Q3 24 | $1.2B | $571.3M | ||
| Q2 24 | $1.2B | $577.4M | ||
| Q1 24 | $1.2B | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-78.1M | $27.3M |
| Free Cash FlowOCF − Capex | $-83.1M | $16.3M |
| FCF MarginFCF / Revenue | -99.7% | 13.1% |
| Capex IntensityCapex / Revenue | 6.0% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-124.2M | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-78.1M | $27.3M | ||
| Q3 25 | $11.1M | $-8.1M | ||
| Q2 25 | $-30.2M | $40.8M | ||
| Q1 25 | $-4.4M | $-9.8M | ||
| Q4 24 | $25.0M | $-7.4M | ||
| Q3 24 | $-15.5M | $-30.8M | ||
| Q2 24 | $4.3M | $43.7M | ||
| Q1 24 | $7.3M | $25.2M |
| Q4 25 | $-83.1M | $16.3M | ||
| Q3 25 | $5.1M | $-12.4M | ||
| Q2 25 | $-37.0M | $33.5M | ||
| Q1 25 | $-9.1M | $-16.1M | ||
| Q4 24 | $21.2M | $-10.7M | ||
| Q3 24 | $-35.0M | $-35.5M | ||
| Q2 24 | $-8.7M | $38.2M | ||
| Q1 24 | $3.2M | $7.0M |
| Q4 25 | -99.7% | 13.1% | ||
| Q3 25 | 6.0% | -14.6% | ||
| Q2 25 | -45.2% | 23.8% | ||
| Q1 25 | -12.5% | -13.9% | ||
| Q4 24 | 27.9% | -8.3% | ||
| Q3 24 | -48.8% | -40.2% | ||
| Q2 24 | -12.2% | 24.0% | ||
| Q1 24 | 5.0% | 5.1% |
| Q4 25 | 6.0% | 8.8% | ||
| Q3 25 | 7.2% | 5.0% | ||
| Q2 25 | 8.3% | 5.2% | ||
| Q1 25 | 6.4% | 5.4% | ||
| Q4 24 | 5.0% | 2.5% | ||
| Q3 24 | 27.2% | 5.3% | ||
| Q2 24 | 18.2% | 3.5% | ||
| Q1 24 | 6.3% | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | — | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLGT
| Precision Diagnostics | $48.3M | 58% |
| Anatomic Pathology | $27.0M | 32% |
| Biopharma Services | $7.8M | 9% |
SWBI
Segment breakdown not available.
